Patent 11834449 was granted and assigned to Takeda Pharmaceutical Company on December, 2023 by the United States Patent and Trademark Office.
The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.